Lord David Cameron, the former prime minister, has publicly disclosed his diagnosis and subsequent treatment for prostate cancer, urging the implementation of a targeted screening programme in the UK. The 59-year-old was prompted to get tested by his wife, Samantha, after they heard Soho House founder Nick Jones discuss his own prostate cancer journey on the radio.

Cameron underwent a prostate-specific antigen (PSA) test, which showed a high result, followed by an MRI scan and a biopsy. The biopsy confirmed the presence of prostate cancer, a moment he described as dread-inducing: “You always dread hearing those words. And then literally as they're coming out of the doctor's mouth you're thinking, 'Oh, no, he's going to say it. He's going to say it. Oh God, he said it.'” Following his diagnosis, Lord Cameron opted for focal therapy, a less invasive treatment using electric pulses to destroy cancerous cells, which proved successful, and he is now cancer-free.

Motivated by his personal experience, Cameron has called for a nationwide targeted screening programme. He stated, “I want to, as it were, come out. I want to add my name to the long list of people calling for a targeted screening programme. I don’t particularly like discussing my personal intimate health issues, but I feel I ought to. Let’s be honest. Men are not very good at talking about their health. We tend to put things off.” This call for action is backed by Olympic cycling legend Sir Chris Hoy, who was diagnosed with stage four prostate cancer in September 2023.

Prostate cancer remains the most common cancer in males in the UK, with approximately 55,000 to 63,000 new cases and about 12,000 deaths annually. Currently, the UK lacks a widespread national screening programme for the disease, largely due to historical concerns about the accuracy of PSA tests and the risk of overdiagnosis. However, advancements in technology have made these concerns less prohibitive.

Significantly, Cameron's announcement comes as new initiatives and decisions are underway. The first eligible men in the UK were recently invited to participate in the 'Transform' project, a major trial comparing promising screening techniques with current NHS diagnostic processes, supported by £16 million from the National Institute for Health and Care Research and additional funding from Prostate Cancer UK. Furthermore, the UK National Screening Committee (NSC) is poised to make a crucial decision regarding whether current evidence supports the introduction of screening. It is anticipated that any approved programme would likely be targeted at high-risk individuals, such as those with a family history or specific genetic predispositions. Major studies, including one from the University Medical Centre Rotterdam, have shown that screening can reduce the risk of dying from prostate cancer by 13 percent, leading to a sustained drop in deaths over decades, preventing one death for every 456 men invited for PSA tests.